Stockscreener 앱 받기
11.15
0.96%
0.0793
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Pliant Therapeutics appoints new Chief Technical Officer - Investing.com
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer - GlobeNewswire
Pliant Therapeutics Strengthens Leadership Team with Veteran CTO Appointment for Commercial Push - StockTitan
Analysts Set Expectations for PLRX FY2025 Earnings - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis - Defense World
PLRX (Pliant Therapeutics) 3-Year EPS without NRI Growth Ra - GuruFocus.com
PLRX (Pliant Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.2%Here's Why - MarketBeat
Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 11%Still a Buy? - MarketBeat
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Pliant Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Position Boosted by Geode Capital Management LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.9%Time to Sell? - MarketBeat
Contrasting Pliant Therapeutics (NASDAQ:PLRX) & Bionomics (NASDAQ:BNOX) - Defense World
When (PLRX) Moves Investors should Listen - Stock Traders Daily
State Street Corp Raises Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts - MarketBeat
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 3.6%Should You Buy? - MarketBeat
The Manufacturers Life Insurance Company Cuts Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
(PLRX) Trading Signals - Stock Traders Daily
Pliant Therapeutics (STU:9PT) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.57 Average Target Price from Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Great Point Partners LLC Has $21.41 Million Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics (STU:9PT) Change In Inventory : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Atria Investments Inc Takes Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
PLRX (Pliant Therapeutics) Market Cap : $789.88 Mil (As of Nov. 24, 2024) - GuruFocus.com
PLRX (Pliant Therapeutics) Earnings Yield % : N/A% (As of Nov. 24, 2024) - GuruFocus.com
Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan
Vietnamese Dong/Canadian Dollar (VNDCAD) QuotePress Release - The Globe and Mail
Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire
Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan
Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com
First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com
Objective long/short (PLRX) Report - Stock Traders Daily
Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK
Fresh Del Monte Produce (FDP-N) QuotePress Release - The Globe and Mail
Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK
HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
0.98%
7.55%
자본화:
|
볼륨(24시간):